InflaRx Reports on Nasdaq Bid Price Compliance Status
InflaRx's Notice from Nasdaq Regarding Minimum Bid Price
InflaRx N.V., a leading biopharmaceutical company known for its innovative anti-inflammatory therapeutics, has received a notification from Nasdaq regarding its stock price. This notice indicates that for the last thirty consecutive business days, the closing bid price of the company’s common shares has fallen below the minimum requirement of $1.00 per share. This situation activates Nasdaq's Listing Rule 5450(a)(1), referred to as the Minimum Bid Price Rule.
Understanding the Compliance Period
According to Nasdaq Listing Rule 5810(c)(3)(A), InflaRx has been granted an initial period of 180 calendar days to rectify this situation. The deadline for compliance has been set for January 7, 2026. If the company fails to meet this requirement by that date, it may explore transferring its securities to The Nasdaq Capital Market, provided it meets necessary criteria besides the bid price requirement. Such a transfer would allow for an additional 180 days to comply.
Monitoring Share Prices and Future Actions
The company is committed to closely observing the bid price of its shares and will explore all available options to regain compliance with the Minimum Bid Price Rule. It is important to note that the notice has no immediate impact on the trading of InflaRx's shares.
About InflaRx N.V.
InflaRx (Nasdaq: IFRX) specializes in pioneering anti-inflammatory therapeutics through its proprietary anti-C5a and anti-C5a receptor technologies. The company aims to develop highly effective inhibitors of the complement activation factor C5a, a critical mediator in various inflammatory diseases. A highlight of their portfolio is vilobelimab, an innovative intravenously delivered, first-in-class monoclonal antibody that selectively binds to free C5a, showcasing significant clinical efficacy and safety in multiple studies.
Company Background and Global Presence
Founded in 2007, InflaRx has established a strong presence in the biopharmaceutical sector, with offices in Germany and the USA. The company’s innovative approach to managing inflammation has positioned it at the forefront of biopharmaceutical research. Besides it, InflaRx is in the process of developing INF904, an orally administered small molecule aimed at inhibiting C5a-induced signaling through the C5a receptor.
Company Contacts
For further information, InflaRx N.V. can be reached through Jan Medina, CFA, Vice President, Head of Investor Relations, via email at IR@inflarx.de. For additional queries in Europe, the team at MC Services AG, led by Katja Arnold, can be contacted at inflarx@mc-services.eu, with phone lines available for Germany and the USA.
Frequently Asked Questions
What prompted InflaRx to receive a notice from Nasdaq?
InflaRx received a notice from Nasdaq due to its stock price falling below the minimum required bid price of $1.00 for 30 consecutive business days.
How long does InflaRx have to regain compliance?
The company has an initial period of 180 calendar days, until January 7, 2026, to regain compliance with Nasdaq's Minimum Bid Price Rule.
What will happen if InflaRx does not comply within the given period?
If compliance is not achieved by the deadline, InflaRx may consider transferring its securities to The Nasdaq Capital Market, which can offer an additional compliance period.
Is there an immediate impact on InflaRx's trading?
No, the notice does not have any immediate effects on the listing or trading of InflaRx’s common shares.
What is the primary objective of InflaRx?
InflaRx aims to develop and commercialize anti-inflammatory therapeutics by targeting the complement system, with innovative products like vilobelimab at the forefront.
About The Author
Contact Riley Hayes privately here. Or send an email with ATTN: Riley Hayes as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
